Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-826: Pembrolizumab plus chemotherapy versus chemotherapy plus placebo in first-line treatment of persistent, recurrent, or metastatic cervical cancer
2018-001440-53Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Pembrolizumab plus chemotherapy with Chemotherapy plus placebo (2 arms). Primary endpoint: Progression-free survival (PFS). Started Aug 2018; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2018-001440-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001440-53.